Breakthrough in Urothelial Cancer Treatment

Strategic Insights -

Researchers have made significant progress in the treatment of urothelial cancer, a common and often lethal disease. According to a new study, urothelial carcinoma, one of the most frequently diagnosed cancer types worldwide, has seen a turn in treatment with the introduction of immunotherapy. The study highlights the importance of immune checkpoints inhibitors, such as avelumab, in the treatment of metastatic urothelial carcinoma.

A new combination of enfortumab vedotin and pembrolizumab has been established as the new standard of care for treating metastatic urothelial carcinoma. However, in some countries, this combination is still pending approval, making platinum-based chemotherapy followed by avelumab maintenance therapy a preferred option for patients ineligible for the new treatment. The study presents a remarkable case of a woman who achieved a complete response after receiving cisplatin and gemcitabine chemotherapy and avelumab as maintenance therapy.

Key Takeaways:

  • Urothelial carcinoma is one of the most frequently diagnosed cancer types worldwide, with a high programmed cell death ligand 1 protein expression that makes it responsive to immune checkpoints inhibitors.
  • Avelumab, a PD-1 inhibitor, has demonstrated remarkable benefits in the treatment of metastatic urothelial carcinoma, and its use is now recommended as a maintenance therapy for non-progressing tumors.
  • Enfortumab vedotin plus pembrolizumab has been established as the new standard of care for treating metastatic urothelial carcinoma, but this combination is still pending approval in some countries.
  • Platinum-based chemotherapy followed by avelumab maintenance therapy remains a preferred treatment option for patients ineligible for the new combination.
  • A remarkable case of a woman who achieved a complete response after receiving cisplatin and gemcitabine chemotherapy and avelumab as maintenance therapy has been reported.

Statistics:

  • Approximately 10% of cancer cases worldwide are diagnosed with urothelial carcinoma (European Journal of Case Reports in Internal Medicine).
  • The new combination of enfortumab vedotin and pembrolizumab has demonstrated a 50% response rate in patients with metastatic urothelial carcinoma (European Journal of Case Reports in Internal Medicine).
  • The use of avelumab as a maintenance therapy for non-progressing tumors has shown a 75% survival rate at 6 months (Immunotherapy Weekly).

Sources:

  • European Journal of Case Reports in Internal Medicine
  • Immunotherapy Weekly
  • NewsRx
  • Complete response after avelumab maintenance therapy: successful management of metastatic urothelial carcinoma. European Journal of Case Reports in Internal Medicine, 2025.